Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Nasal congestion, Rhinorrhoea, SARS-CoV-2 test
Clinical narrative: Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.; Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.; Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.), NASAL CONGESTION (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) and RHINORRHOEA (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027l21) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Allergy, Asthma and Lung cancer. Concomitant products included BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for an unknown indication.   On 22-Feb-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Apr-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) 1 dosage form. On 28-Apr-2022, the patient experienced NASAL CONGESTION (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) and RHINORRHOEA (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.). On an unknown date, the patient experienced COVID-19 (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.). At the time of the report, COVID-19 (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) outcome was unknown and NASAL CONGESTION (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) and RHINORRHOEA (Tested positive for covid. Eleven days later, I again tested positive and had  congestion in my nose and a runny nose.) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive and positive (Positive) Positive.         It was reported that patient tested positive for covid. Took Paxlovid for five days. Felt great after two days. Device date was reported as 29-Apr-2022  Company Comment:  This spontaneous case concerns a 79-year-old male patient with concurrent asthma and lung cancer, who experienced the unexpected non-serious adverse event of special interest COVID-19 on an unknown date after receiving the fourth dose of mRNA-1273 vaccine in the COVID-19 vaccination schedule.  Patient tested positive for COVID-19 on an unspecified date and was given NIRMATRELVIR, RITONAVIR (Paxlovid) for five days with improvement of condition noted after 2 days of treatment.  Patient had tested positive again for COVID-19 eleven days later with symptoms of nasal congestion and runny nose.  No information was provided on the previous 3 COVID-19 vaccination. The concurrent asthma and lung cancer could be considered as contributory risk factors. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 79-year-old male patient with concurrent asthma and lung cancer, who experienced the unexpected non-serious adverse event of special interest COVID-19 on an unknown date after receiving the fourth dose of mRNA-1273 vaccine in the COVID-19 vaccination schedule.  Patient tested positive for COVID-19 on an unspecified date and was given NIRMATRELVIR, RITONAVIR (Paxlovid) for five days with improvement of condition noted after 2 days of treatment.  Patient had tested positive again for COVID-19 eleven days later with symptoms of nasal congestion and runny nose.  No information was provided on the previous 3 COVID-19 vaccination. The concurrent asthma and lung cancer could be considered as contributory risk factors. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.